We are live on ! Find out more
LBRX

LB Pharmaceuticals
LBRX

68 hedge funds and large institutions have $552M invested in LB Pharmaceuticals in 2025 Q4 according to their latest regulatory filings, with 33 funds opening new positions, 13 increasing their positions, 12 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more funds holding in top 10

Funds holding in top 10: 1 → 3 (+2)

106% more first-time investments, than exits

New positions opened: 33 | Existing positions closed: 16

75% more capital invested

Capital invested by funds: $315M → $552M (+$237M)

28% more funds holding

Funds holding: 53 → 68 (+15)

8% more repeat investments, than reductions

Existing positions increased: 13 | Existing positions reduced: 12

1.19% less ownership

Funds ownership: 99.18% → 97.99% (-1.2%)

Holders
68
Holders Change
+15
Holders Change %
+28.3%
% of All Funds
0.83%
Holding in Top 10
3
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+200%
% of All Funds
0.04%
New
33
Increased
13
Reduced
12
Closed
16
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$22.1M
2
Vanguard Group
Vanguard Group
Pennsylvania
+$19.4M
3
JP Morgan Chase
JP Morgan Chase
New York
+$10.1M
4
RCM
RA Capital Management
Massachusetts
+$7.54M
5
Geode Capital Management
Geode Capital Management
Massachusetts
+$7.47M

Top Sellers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
-$8.5M
2
SCM
Soleus Capital Management
Connecticut
-$6.81M
3
Wellington Management Group
Wellington Management Group
Massachusetts
-$5.44M
4
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$4.74M
5
Marshall Wace
Marshall Wace
United Kingdom
-$4.15M
Name Holding Trade Value Shares
Change 		Change in
Stake
DTC
1
Deep Track Capital
Connecticut
$74.6M – – –
BlackRock
2
BlackRock
New York
$49.8M +$22.1M +1,263,934 +130%
RCM
3
RA Capital Management
Massachusetts
$49.2M +$7.54M +431,646 +24%
TCM
4
TCG Crossover Management
California
$38.8M -$17 -1 -0%
JP Morgan Chase
5
JP Morgan Chase
New York
$35.9M +$10.1M +578,879 +56%
CC
6
Commodore Capital
New York
$33.4M – – –
TECP
7
Trails Edge Capital Partners
Georgia
$31.1M +$24.4M +1,395,608 New
LGM
8
Logos Global Management
California
$26.7M +$1.22M +70,000 +6%
Vanguard Group
9
Vanguard Group
Pennsylvania
$24.8M +$19.4M +1,112,978 New
SSC
10
Spruce Street Capital
New York
$22.4M +$17.6M +1,005,593 New
Balyasny Asset Management
11
Balyasny Asset Management
Illinois
$20M -$1.25M -71,468 -7%
Jennison Associates
12
Jennison Associates
New York
$18.3M +$1.45M +82,812 +11%
VC
13
Vivo Capital
California
$17.8M – – –
Alyeska Investment Group
14
Alyeska Investment Group
Illinois
$15M – – –
NCM
15
Nantahala Capital Management
Connecticut
$15M – – –
Geode Capital Management
16
Geode Capital Management
Massachusetts
$9.83M +$7.47M +427,863 +3,148%
Citadel Advisors
17
Citadel Advisors
Florida
$9.07M -$2.3M -131,702 -24%
Goldman Sachs
18
Goldman Sachs
New York
$6.75M -$706K -40,408 -12%
NFGH
19
Nan Fung Group Holdings
Hong Kong
$6.68M – – –
State Street
20
State Street
Massachusetts
$5.57M +$4.37M +250,030 New
Fidelity Investments
21
Fidelity Investments
Massachusetts
$4.94M -$2.57M -147,235 -40%
BBA
22
Baker Bros. Advisors
New York
$4.45M – – –
Ameriprise
23
Ameriprise
Minnesota
$4.31M +$2.03M +116,094 +150%
Charles Schwab
24
Charles Schwab
California
$3.95M +$3.1M +177,616 New
Northern Trust
25
Northern Trust
Illinois
$3.2M +$2.51M +143,966 New
1
2 3 4

LBRX Hedge Fund Activity: Q4 2025 in Review

68 of the 8,223 institutional investors tracked by Wall St. Rank reported a position in LB Pharmaceuticals (LBRX) for Q4 2025, worth a combined $552M — up 75% from $315M a quarter earlier.

Buyers outnumbered sellers: 33 funds opened new LBRX positions and 16 closed out — a net gain of 17 holders — while 13 added to existing stakes and 12 trimmed.

The largest buyer was BlackRock, adding an estimated $22.1M. The largest seller was Millennium Management, exiting entirely with an estimated $8.5M sold.

  • 68 institutional investors held LB Pharmaceuticals (LBRX) as of Q4 2025, up from 53 in Q3 2025.
  • Funds reported $552M of LB Pharmaceuticals stock for Q4 2025, up 75% quarter-over-quarter.
  • 33 funds opened new LB Pharmaceuticals positions in Q4 2025 and 16 closed out, a net change of +17 holders.
  • The largest LB Pharmaceuticals buyer in Q4 2025 was BlackRock, an estimated $22.1M added.
  • The largest LB Pharmaceuticals seller in Q4 2025 was Millennium Management, an estimated $8.5M sold.

Based on aggregated 13F filings for Q4 2025.